Athersys (Athersys) EBIT per Share : $-2.21 (TTM As of Sep. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Athersys EBIT per Share?

Athersys's EBIT per Share for the three months ended in Sep. 2023 was $-0.32. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $-2.21.

During the past 3 years, the average EBIT per Share Growth Rate was -178.00% per year. During the past 5 years, the average EBIT per Share Growth Rate was -140.90% per year. During the past 10 years, the average EBIT per Share Growth Rate was -39.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Athersys's EBIT per Share or its related term are showing as below:

ATHXQ' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -272.3 Med: 15.25 Max: 76.6
Current: -178

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Athersys was 76.60% per year. The lowest was -272.30% per year. And the median was 15.25% per year.

ATHXQ's 3-Year EBIT Growth Rate is ranked worse than
98.93% of 1305 companies
in the Biotechnology industry
Industry Median: 3.6 vs ATHXQ: -178.00

Athersys's EBIT for the three months ended in Sep. 2023 was $-7.78 Mil.

Athersys EBIT per Share Historical Data

The historical data trend for Athersys's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Athersys EBIT per Share Chart

Athersys Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EBIT per Share

Get a 7-Day Free Trial

-0.19

-0.30

-10.45

-9.70

-6.45

Athersys Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EBIT per Share	Get a 7-Day Free Trial															-1.41	-0.87	-0.40	-0.63	-0.32

Athersys EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Athersys's EBIT per Share for the fiscal year that ended in Dec. 2022 is calculated as

	EBIT per Share		(A: Dec. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-77.009	/	11.945
=	-6.45

Athersys's EBIT per Share for the quarter that ended in Sep. 2023 is calculated as

	EBIT per Share		(Q: Sep. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-7.78	/	24.492
=	-0.32

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.21

Athersys (OTCPK:ATHXQ) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Athersys EBIT per Share Related Terms

Thank you for viewing the detailed overview of Athersys's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Athersys (Athersys) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Athersys Inc (OTCPK:ATHXQ) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

3201 Carnegie Avenue, Cleveland, OH, USA, 44115-2634

Website

https://www.athersys.com

Athersys Inc is a biotechnology company engaged in the field of regenerative medicine. It consists of research, clinical development, manufacturing, and manufacturing process development activities. The firm's main product is Multistem cell therapy. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and certain pulmonary conditions. Its revenue has been derived from corporate collaborations, license agreements, and government grants.

Executives

Neema Mayhugh	director	3201 CARNEGIE AVE, CLEVELAND OH 44115
Joseph Patrick Nolan	director	100 PARK LANE, LAKE BLUFF IL 60044
Daniel A. Camardo	director, officer: Chief Executive Officer	ATHERSYS, INC., 3201 CARNEGIE AVE, CLEVELAND OH 44115
Maia Hansen	officer: Chief Operating Officer	16430 N. SCOTTSDALE ROAD, SCOTTSDALE AZ 85254
Kasey Rosado	officer: Interim, CFO	485 LEXINGTON AVE 10TH FLOOR, NEW YORK NY 10017
Ismail Kola	director	3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Ivor Macleod	officer: Chief Financial Officer	3201 CARNEGIE AVENUE, CLEVELAND OH 44115-2634
William Jr Lehmann	officer: President	3201 CARNEGIE AVENUE, CLEVELAND OH 44115
John J Harrington	director, officer: Chief Scientific Officer	3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Laura K Campbell	officer: Vice President	3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Katherine Bach Kalin	director	3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Baiju R. Shah	director	ONE INVACARE WAY, ELYRIA OH 44035
Jane Wasman	director	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Kenneth H Traub	director
Tadahisa Kagimoto	director, 10 percent owner	HEALIOS K.K., WORLD TRADE CENTER BLDG., 15F, 2-4-1 HAMAMATSUCHO, MINATO-KU, TOKYO M0 1056115